Vpu protein: The viroporin encoded by HIV-1

Viruses

Volumn 7, Issue 8, 2015, Pages 4352-4368

  González, María Eugenia ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antiretroviral target; HIV 1; Ion; Membrane permeability; Membrane pore; Protein trafficking; Transport; Viroporin; Vpu

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING E3 UBIQUITIN PROTEIN LIGASE; BONE MARROW STROMAL CELL ANTIGEN 2; CD155 ANTIGEN; CD1D ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD81 ANTIGEN; CELL ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAG PROTEIN; GLYCOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NTB A PROTEIN; POTASSIUM CHANNEL; TASK 1 PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VPU PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; PROTEIN BINDING; VIRAL PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; DOWN REGULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLEIOTROPY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; TRANS GOLGI NETWORK; VIRUS RELEASE; VIRUS STRAIN; BIOSYNTHESIS; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT;

ANTIGENS, CD4; DOWN-REGULATION; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS RELEASE;

EID: 84941032734     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7082824     Document Type: Review

References (114)

1. Cohen, A.; Terwilliger, E.F.; Sodroski, J.G.; Haseltine, W.A. Identification of a protein encoded by the vpu gene of HIV-1. Nature 1988, 334, 532-534. [CrossRef] [PubMed]
2. Strebel, K.; Klimkait, T.; Martin, M.A. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 1988, 241, 1221-1223. [CrossRef] [PubMed]
3. Carrasco, L. Modification of membrane permeability by animal viruses. Adv. Virus Res. 1995, 45, 61-112. [PubMed]
4. Gonzalez, M.E.; Carrasco, L. Viroporins. FEBS Lett. 2003, 552, 28-34. [CrossRef]
5. Nieva, J.L.; Madan, V.; Carrasco, L. Viroporins: Structure and biological functions. Nat. Rev. Microbiol. 2012, 10, 563-574. [CrossRef] [PubMed]
6. Schwartz, S.; Felber, B.K.; Fenyo, E.M.; Pavlakis, G.N. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J. Virol. 1990, 64, 5448-5456. [PubMed]
7. Willey, R.L.; Maldarelli, F.; Martin, M.A.; Strebel, K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 1992, 66, 7193-7200. [PubMed]
8. Strebel, K.; Klimkait, T.; Maldarelli, F.; Martin, M.A. Molecular and biochemical analyses of human immunodeficiency virus type 1 Vpu protein. J. Virol. 1989, 63, 3784-3791. [PubMed]
9. Marassi, F.M.; Ma, C.; Gratkowski, H.; Straus, S.K.; Strebel, K.; Oblatt-Montal, M.; Montal, M.; Opella, S.J. Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1. Proc. Natl. Acad. Sci. USA 1999, 96, 14336-14341. [CrossRef] [PubMed]
10. Schubert, U.; Bour, S.; Ferrer-Montiel, A.V.; Montal, M.; Maldarelli, F.; Strebel, K. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J. Virol. 1996, 70, 809-819. [PubMed]
11. Willey, R.L.; Maldarelli, F.; Martin, M.A.; Strebel, K. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J. Virol. 1992, 66, 226-234. [PubMed]
12. Geraghty, R.J.; Panganiban, A.T. Human immunodeficiency virus type 1 Vpu has a CD4-and an envelope glycoprotein-independent function. J. Virol. 1993, 67, 4190-4194. [PubMed]
13. Wray, V.; Federau, T.; Henklein, P.; Klabunde, S.; Kunert, O.; Schomburg, D.; Schubert, U. Solution structure of the hydrophilic region of HIV-1 encoded virus protein U (Vpu) by CD and 1H NMR spectroscopy. Int. J. Pept. Protein Res. 1995, 45, 35-43. [CrossRef] [PubMed]
14. Chen, M.Y.; Maldarelli, F.; Karczewski, M.K.; Willey, R.L.; Strebel, K. Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: The cytoplasmic domain of CD4 contributes to Vpu sensitivity. J. Virol. 1993, 67, 3877-3884. [PubMed]
15. Schubert, U.; Strebel, K. Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J. Virol. 1994, 68, 2260-2271. [PubMed]
16. Veillette, M.; Desormeaux, A.; Medjahed, H.; Gharsallah, N.E.; Coutu, M.; Baalwa, J.; Guan, Y.; Lewis, G.; Ferrari, G.; Hahn, B.H.; et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J. Virol. 2014, 88, 2633-2644. [CrossRef] [PubMed]
17. Pham, T.N.; Lukhele, S.; Hajjar, F.; Routy, J.P.; Cohen, E.A. HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology 2014, 11, e15. [CrossRef] [PubMed]
18. Balliet, J.W.; Kolson, D.L.; Eiger, G.; Kim, F.M.; McGann, K.A.; Srinivasan, A.; Collman, R. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef : Mutational analysis of a primary HIV-1 isolate. Virology 1994, 200, 623-631. [CrossRef] [PubMed]
19. Geraghty, R.J.; Talbot, K.J.; Callahan, M.; Harper, W.; Panganiban, A.T. Cell type-dependence for Vpu function. J. Med. Primatol. 1994, 23, 146-150. [CrossRef] [PubMed]
20. Sakai, H.; Tokunaga, K.; Kawamura, M.; Adachi, A. Function of human immunodeficiency virus type 1 Vpu protein in various cell types. J. Gen. Virol. 1995, 76, 2717-2722. [CrossRef] [PubMed]
21. Ewart, G.D.; Sutherland, T.; Gage, P.W.; Cox, G.B. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J. Virol. 1996, 70, 7108-7115. [PubMed]
22. Deora, A.; Ratner, L. Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation. J. Virol. 2001, 75, 6714-6718. [CrossRef] [PubMed]
23. Neil, S.J.; Sandrin, V.; Sundquist, W.I.; Bieniasz, P.D. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007, 2, 193-203. [CrossRef] [PubMed]
24. Neil, S.J.; Zang, T.; Bieniasz, P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451, 425-430. [CrossRef] [PubMed]
25. Kupzig, S.; Korolchuk, V.; Rollason, R.; Sugden, A.; Wilde, A.; Banting, G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003, 4, 694-709. [CrossRef] [PubMed]
26. Perez-Caballero, D.; Zang, T.; Ebrahimi, A.; McNatt, M.W.; Gregory, D.A.; Johnson, M.C.; Bieniasz, P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139, 499-511. [CrossRef] [PubMed]
27. Van, D.N.; Goff, D.; Katsura, C.; Jorgenson, R.L.; Mitchell, R.; Johnson, M.C.; Stephens, E.B.; Guatelli, J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3, 245-252.
28. Goffinet, C.; Allespach, I.; Homann, S.; Tervo, H.M.; Habermann, A.; Rupp, D.; Oberbremer, L.; Kern, C.; Tibroni, N.; Welsch, S.; et al. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009, 5, 285-297. [CrossRef] [PubMed]
29. Iwabu, Y.; Fujita, H.; Kinomoto, M.; Kaneko, K.; Ishizaka, Y.; Tanaka, Y.; Sata, T.; Tokunaga, K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 2009, 284, 35060-35072. [CrossRef] [PubMed]
30. McNatt, M.W.; Zang, T.; Hatziioannou, T.; Bartlett, M.; Fofana, I.B.; Johnson, W.E.; Neil, S.J.; Bieniasz, P.D. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 2009, 5, e1000300. [CrossRef] [PubMed]
31. Dube, M.; Roy, B.B.; Guiot-Guillain, P.; Mercier, J.; Binette, J.; Leung, G.; Cohen, E.A. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J. Virol. 2009, 83, 4574-4590. [CrossRef] [PubMed]
32. Lewinski, M.K.; Jafari, M.; Zhang, H.; Opella, S.J.; Guatelli, J. Membrane Anchoring by a C-terminal Tryptophan Enables HIV-1 Vpu to Displace Bone Marrow Stromal Antigen 2 (BST2) from Sites of Viral Assembly. J. Biol. Chem. 2015, 290, 10919-10933. [CrossRef] [PubMed]
33. Maldarelli, F.; Chen, M.Y.; Willey, R.L.; Strebel, K. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J. Virol. 1993, 67, 5056-5061. [PubMed]
34. Pinto, L.H.; Holsinger, L.J.; Lamb, R.A. Influenza virus M2 protein has ion channel activity. Cell 1992, 69, 517-528. [CrossRef]
35. Grice, A.L.; Kerr, I.D.; Sansom, M.S. Ion channels formed by HIV-1 Vpu: A modelling and simulation study. FEBS Lett. 1997, 405, 299-304. [CrossRef]
36. Schubert, U.; Ferrer-Montiel, A.V.; Oblatt-Montal, M.; Henklein, P.; Strebel, K.; Montal, M. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett. 1996, 398, 12-18. [CrossRef]
37. Coady, M.J.; Daniel, N.G.; Tiganos, E.; Allain, B.; Friborg, J.; Lapointe, J.Y.; Cohen, E.A. Effects of Vpu expression on Xenopus oocyte membrane conductance. Virology 1998, 244, 39-49. [CrossRef] [PubMed]
38. Ma, C.; Marassi, F.M.; Jones, D.H.; Straus, S.K.; Bour, S.; Strebel, K.; Schubert, U.; Oblatt-Montal, M.; Montal, M.; Opella, S.J. Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci. 2002, 11, 546-557. [CrossRef] [PubMed]
39. Hsu, K.; Han, J.; Shinlapawittayatorn, K.; Deschenes, I.; Marban, E. Membrane potential depolarization as a triggering mechanism for Vpu-mediated HIV-1 release. Biophys. J. 2010, 99, 1718-1725. [CrossRef] [PubMed]
40. Hsu, K.; Seharaseyon, J.; Dong, P.; Bour, S.; Marban, E. Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. Mol. Cell 2004, 14, 259-267. [CrossRef]
41. Herrero, L.; Monroy, N.; Gonzalez, M.E. HIV-1 Vpu protein mediates the transport of potassium in Saccharomyces cerevisiae. Biochemistry 2013, 52, 171-177. [CrossRef] [PubMed]
42. Sato, H.; Orenstein, J.; Dimitrov, D.; Martin, M. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 1992, 186, 712-724. [CrossRef]
43. Klimkait, T.; Strebel, K.; Hoggan, M.D.; Martin, M.A.; Orenstein, J.M. The human immunodeficiency virus type 1-specific protein Vpu is required for efficient virus maturation and release. J. Virol. 1990, 64, 621-629. [PubMed]
44. Lu, J.X.; Sharpe, S.; Ghirlando, R.; Yau, W.M.; Tycko, R. Oligomerization state and supramolecular structure of the HIV-1 Vpu protein transmembrane segment in phospholipid bilayers. Protein Sci. 2010, 19, 1877-1896. [CrossRef] [PubMed]
45. Estrabaud, E.; Le, R.E.; Lopez-Verges, S.; Morel, M.; Belaidouni, N.; Benarous, R.; Transy, C.; Berlioz-Torrent, C.; Margottin-Goguet, F. Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles. PLoS Pathog. 2007, 3, e104. [CrossRef] [PubMed]
46. Hussain, A.; Das, S.R.; Tanwar, C.; Jameel, S. Oligomerization of the human immunodeficiency virus type 1 (HIV-1) Vpu protein-A genetic, biochemical and biophysical analysis. Virol. J. 2007, 4, e81. [CrossRef] [PubMed]
47. Waheed, A.A.; Freed, E.O. The Role of Lipids in Retrovirus Replication. Viruses 2010, 2, 1146-1180. [CrossRef] [PubMed]
48. Tokarev, A.; Guatelli, J. Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence. Cell. Logist. 2011, 1, 90-102. [CrossRef] [PubMed]
49. Ramirez, P.W.; Famiglietti, M.; Sowrirajan, B.; DePaula-Silva, A.B.; Rodesch, C.; Barker, E.; Bosque, A.; Planelles, V. Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4(+) T cells. Cell Rep. 2014, 7, 2019-2030. [CrossRef] [PubMed]
50. Moll, M.; Andersson, S.K.; Smed-Sorensen, A.; Sandberg, J.K. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood 2010, 116, 1876-1884. [CrossRef] [PubMed]
51. Bachle, S.M.; Sauter, D.; Sibitz, S.; Sandberg, J.K.; Kirchhoff, F.; Moll, M. Involvement of a C-terminal motif in the interference of primate lentiviral Vpu proteins with CD1d-mediated antigen presentation. Sci. Rep. 2015, 5, 9675. [CrossRef] [PubMed]
52. Henderson, W.W.; Ruhl, R.; Lewis, P.; Bentley, M.; Nelson, J.A.; Moses, A.V. Human immunodeficiency virus (HIV) type 1 Vpu induces the expression of CD40 in endothelial cells and regulates HIV-induced adhesion of B-lymphoma cells. J. Virol. 2004, 78, 4408-4420. [CrossRef] [PubMed]
53. Lambele, M.; Koppensteiner, H.; Symeonides, M.; Roy, N.H.; Chan, J.; Schindler, M.; Thali, M. Vpu is the main determinant for tetraspanin downregulation in HIV-1-infected cells. J. Virol. 2015, 89, 3247-3255. [CrossRef] [PubMed]
54. Matusali, G.; Potesta, M.; Santoni, A.; Cerboni, C.; Doria, M. The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J. Virol. 2012, 86, 4496-4504. [CrossRef] [PubMed]
55. Bolduan, S.; Reif, T.; Schindler, M.; Schubert, U. HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain. Virology 2014, 464-465, 375-384. [CrossRef] [PubMed]
56. Vassena, L.; Giuliani, E.; Koppensteiner, H.; Bolduan, S.; Schindler, M.; Doria, M. HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4+ T Lymphocytes. J. Virol. 2015, 89, 5687-5700. [CrossRef] [PubMed]
57. Kerkau, T.; Bacik, I.; Bennink, J.R.; Yewdell, J.W.; Hunig, T.; Schimpl, A.; Schubert, U. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J. Exp. Med. 1997, 185, 1295-1305. [CrossRef] [PubMed]
58. Shah, A.H.; Sowrirajan, B.; Davis, Z.B.; Ward, J.P.; Campbell, E.M.; Planelles, V.; Barker, E. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 2010, 8, 397-409. [CrossRef] [PubMed]
59. Richard, J.; Cohen, E.A. HIV-1 Vpu disarms natural killer cells. Cell Host Microbe 2010, 8, 389-391. [CrossRef] [PubMed]
60. Jia, X.; Weber, E.; Tokarev, A.; Lewinski, M.; Rizk, M.; Suarez, M.; Guatelli, J.; Xiong, Y. Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1. Elife 2014, 3, e02362. [CrossRef] [PubMed]
61. Besnard-Guerin, C.; Belaidouni, N.; Lassot, I.; Segeral, E.; Jobart, A.; Marchal, C.; Benarous, R. HIV-1 Vpu sequesters beta-transducin repeat-containing protein (betaTrCP) in the cytoplasm and provokes the accumulation of beta-catenin and other SCFbetaTrCP substrates. J. Biol. Chem. 2004, 279, 788-795. [CrossRef] [PubMed]
62. Haller, C.; Muller, B.; Fritz, J.V.; Lamas-Murua, M.; Stolp, B.; Pujol, F.M.; Keppler, O.T.; Fackler, O.T. HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins. J. Virol. 2014, 88, 14241-14257. [CrossRef] [PubMed]
63. Van, D.N.; Guatelli, J. HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes. Cell Microbiol. 2008, 10, 1040-1057.
64. Handley, M.A.; Paddock, S.; Dall, A.; Panganiban, A.T. Association of Vpu-binding protein with microtubules and Vpu-dependent redistribution of HIV-1 Gag protein. Virology 2001, 291, 198-207. [CrossRef] [PubMed]
65. Gonzalez, M.E.; Carrasco, L. Human immunodeficiency virus type 1 Vpu protein affects Sindbis virus glycoprotein processing and enhances membrane permeabilization. Virology 2001, 279, 201-209. [CrossRef] [PubMed]
66. Magadan, J.G.; Perez-Victoria, F.J.; Sougrat, R.; Ye, Y.; Strebel, K.; Bonifacino, J.S. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog. 2010, 6, e1000869. [CrossRef] [PubMed]
67. Mangeat, B.; Gers-Huber, G.; Lehmann, M.; Zufferey, M.; Luban, J.; Piguet, V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 2009, 5, e1000574. [CrossRef] [PubMed]
68. Kueck, T.; Neil, S.J. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog. 2012, 8, e1002609. [CrossRef] [PubMed]
69. Margottin, F.; Bour, S.P.; Durand, H.; Selig, L.; Benichou, S.; Richard, V.; Thomas, D.; Strebel, K.; Benarous, R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1998, 1, 565-574. [CrossRef]
70. Douglas, J.L.; Viswanathan, K.; McCarroll, M.N.; Gustin, J.K.; Fruh, K.; Moses, A.V. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J. Virol. 2009, 83, 7931-7947. [CrossRef] [PubMed]
71. Janvier, K.; Pelchen-Matthews, A.; Renaud, J.B.; Caillet, M.; Marsh, M.; Berlioz-Torrent, C. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog. 2011, 7, e1001265. [CrossRef] [PubMed]
72. Petris, G.; Casini, A.; Sasset, L.; Cesaratto, F.; Bestagno, M.; Cereseto, A.; Burrone, O.R. CD4 and BST-2/tetherin proteins retro-translocate from endoplasmic reticulum to cytosol as partially folded and multimeric molecules. J. Biol. Chem. 2014, 289, 1-12. [CrossRef] [PubMed]
73. Miyagi, E.; Andrew, A.J.; Kao, S.; Strebel, K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. USA 2009, 106, 2868-2873. [CrossRef] [PubMed]
74. Neil, S.J.; Eastman, S.W.; Jouvenet, N.; Bieniasz, P.D. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog. 2006, 2, e39. [CrossRef] [PubMed]
75. Gautam, A.; Bhattacharya, J. Evidence that Vpu modulates HIV-1 Gag-envelope interaction towards envelope incorporation and infectivity in a cell type dependent manner. PLoS ONE 2013, 8, e61388. [CrossRef] [PubMed]
76. Balasubramaniam, M.; Freed, E.O. New insights into HIV assembly and trafficking. Physiology 2011, 26, 236-251. [CrossRef] [PubMed]
77. Joshi, A.; Ablan, S.D.; Soheilian, F.; Nagashima, K.; Freed, E.O. Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment. J. Virol. 2009, 83, 5375-5387. [CrossRef] [PubMed]
78. Votteler, J.; Sundquist, W.I. Virus budding and the ESCRT pathway. Cell Host Microbe 2013, 14, 232-241. [CrossRef] [PubMed]
79. Casartelli, N.; Sourisseau, M.; Feldmann, J.; Guivel-Benhassine, F.; Mallet, A.; Marcelin, A.G.; Guatelli, J.; Schwartz, O. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog. 2010, 6, e1000955. [CrossRef] [PubMed]
80. Jolly, C.; Booth, N.J.; Neil, S.J. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J. Virol. 2010, 84, 12185-12199. [CrossRef] [PubMed]
81. Fischer, W.B.; Hsu, H.J. Viral channel forming proteins-modeling the target. Biochim. Biophys. Acta 2011, 1808, 561-571. [CrossRef] [PubMed]
82. Lamb, R.A.; Pinto, L.H. Do Vpu and Vpr of human immunodeficiency virus type 1 and NB of influenza B virus have ion channel activities in the viral life cycles? Virology 1997, 229, 1-11. [CrossRef] [PubMed]
83. Kukol, A.; Arkin, I.T. Vpu transmembrane peptide structure obtained by site-specific fourier transform infrared dichroism and global molecular dynamics searching. Biophys. J. 1999, 77, 1594-1601. [CrossRef]
84. Moore, P.B.; Zhong, Q.; Husslein, T.; Klein, M.L. Simulation of the HIV-1 Vpu transmembrane domain as a pentameric bundle. FEBS Lett. 1998, 431, 143-148. [CrossRef]
85. Gonzalez, M.E.; Carrasco, L. The human immunodeficiency virus type 1 Vpu protein enhances membrane permeability. Biochemistry 1998, 37, 13710-13719. [CrossRef] [PubMed]
86. Mehnert, T.; Routh, A.; Judge, P.J.; Lam, Y.H.; Fischer, D.; Watts, A.; Fischer, W.B. Biophysical characterization of Vpu from HIV-1 suggests a channel-pore dualism. Proteins 2008, 70, 1488-1497. [CrossRef] [PubMed]
87. Nieva, J.L.; Madan, V.; Carrasco, L. Viroporins: Structure and biological functions. Nat. Rev. Microbiol. 2012, 10, 563-574. [CrossRef] [PubMed]
88. Kirchhoff, F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010, 8, 55-67. [CrossRef] [PubMed]
89. Los Alamos HIV Sequence Database and Analysis Staff. HIV Sequence Compendium 2014; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory: Los Alamos, NM, USA, 2014. Available online: http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/ 2014compendium.html (accessed on 30 July 2015).
90. Bour, S.; Strebel, K. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J. Virol. 1996, 70, 8285-8300. [PubMed]
91. Yusim, K.; Kesmir, C.; Gaschen, B.; Addo, M.M.; Altfeld, M.; Brunak, S.; Chigaev, A.; Detours, V.; Korber, B.T. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J. Virol. 2002, 76, 8757-8768. [CrossRef] [PubMed]
92. Sauter, D.; Schindler, M.; Specht, A.; Landford, W.N.; Munch, J.; Kim, K.A.; Votteler, J.; Schubert, U.; Bibollet-Ruche, F.; Keele, B.F.; et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6, 409-421. [CrossRef] [PubMed]
93. Vigan, R.; Neil, S.J. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J. Virol. 2011, 85, 9737-9748. [CrossRef] [PubMed]
94. Kluge, S.F.; Mack, K.; Iyer, S.S.; Pujol, F.M.; Heigele, A.; Learn, G.H.; Usmani, S.M.; Sauter, D.; Joas, S.; Hotter, D.; et al. Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe 2014, 16, 639-650. [CrossRef] [PubMed]
95. Sauter, D. Counteraction of the multifunctional restriction factor tetherin. Front. Microbiol. 2014, 5, e163. [CrossRef] [PubMed]
96. Plantier, J.C.; Leoz, M.; Dickerson, J.E.; De, O.F.; Cordonnier, F.; Lemee, V.; Damond, F.; Robertson, D.L.; Simon, F. A new human immunodeficiency virus derived from gorillas. Nat. Med. 2009, 15, 871-872. [CrossRef] [PubMed]
97. Sharp, P.M.; Hahn, B.H. Origins of HIV and the AIDS pandemic. Cold Spring Harb. Perspect. Med. 2011, 1, a006841. [CrossRef] [PubMed]
98. Sauter, D.; Hue, S.; Petit, S.J.; Plantier, J.C.; Towers, G.J.; Kirchhoff, F.; Gupta, R.K. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology 2011, 8, e103. [CrossRef] [PubMed]
99. Yang, S.J.; Lopez, L.A.; Exline, C.M.; Haworth, K.G.; Cannon, P.M. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 2011, 8, e78. [CrossRef] [PubMed]
100. Sauter, D.; Unterweger, D.; Vogl, M.; Usmani, S.M.; Heigele, A.; Kluge, S.F.; Hermkes, E.; Moll, M.; Barker, E.; Peeters, M.; et al. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog. 2012, 8, e1003093. [CrossRef] [PubMed]
101. McNatt, M.W.; Zang, T.; Bieniasz, P.D. Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog. 2013, 9, e1003299. [CrossRef] [PubMed]
102. Jafari, M.; Guatelli, J.; Lewinski, M.K. Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release. J. Virol. 2014, 88, 5062-5078. [CrossRef] [PubMed]
103. Bolduan, S.; Votteler, J.; Lodermeyer, V.; Greiner, T.; Koppensteiner, H.; Schindler, M.; Thiel, G.; Schubert, U. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317. Virology 2011, 416, 75-85. [CrossRef] [PubMed]
104. Pickering, S.; Hue, S.; Kim, E.Y.; Reddy, S.; Wolinsky, S.M.; Neil, S.J. Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog. 2014, 10, e1003895. [CrossRef] [PubMed]
105. Gonzalez, M.E.; Carrasco, L. Viral proteins that enhance membrane permeability. In Viral Membrane Proteins: Structure, Function and Drug Design; Fischer, W.B., Ed.; Kluwer Academic/Plenum Publishers: New York, NY, USA, 2005; pp. 79-90. Available online: http://rd.springer.com/chapter/10.1007/0-387-28146-0_6#page-1 (accessed on 30 July 2015).
106. Ewart, G.D.; Mills, K.; Cox, G.B.; Gage, P.W. Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur. Biophys. J. 2002, 31, 26-35. [CrossRef] [PubMed]
107. Ewart, G.D.; Nasr, N.; Naif, H.; Cox, G.B.; Cunningham, A.L.; Gage, P.W. Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrob. Agents Chemother. 2004, 48, 2325-2330. [CrossRef]
108. Khoury, G.; Ewart, G.; Luscombe, C.; Miller, M.; Wilkinson, J. Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob. Agents Chemother. 2010, 54, 835-845. [CrossRef] [PubMed]
109. Luscombe, C.A.; Huang, Z.; Murray, M.G.; Miller, M.; Wilkinson, J.; Ewart, G.D. A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antivir. Res. 2010, 86, 144-153. [CrossRef] [PubMed]
110. Hout, D.R.; Gomez, M.L.; Pacyniak, E.; Gomez, L.M.; Fegley, B.; Mulcahy, E.R.; Hill, M.S.; Culley, N.; Pinson, D.M.; Nothnick, W.; et al. Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus (SHIVKU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques. Virology 2006, 344, 541-559. [CrossRef] [PubMed]
111. Hout, D.R.; Gomez, L.M.; Pacyniak, E.; Miller, J.M.; Hill, M.S.; Stephens, E.B. A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine. Virology 2006, 348, 449-461. [CrossRef] [PubMed]
112. Park, S.H.; Opella, S.J. Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: Implications for HIV-1 susceptibility to channel blocking drugs. Protein Sci. 2007, 16, 2205-2215. [CrossRef] [PubMed]
113. Taube, R.; Alhadeff, R.; Assa, D.; Krugliak, M.; Arkin, I.T. Bacteria-based analysis of HIV-1 Vpu channel activity. PLoS ONE 2014, 9, e105387. [CrossRef] [PubMed]
114. Sauter, D.; Schwarz, S.; Wang, K.; Zhang, R.; Sun, B.; Schwarz, W. Genistein as antiviral drug against HIV ion channel. Planta Med. 2014, 80, 682-687. [CrossRef] [PubMed]